Immediate Discharge and Home Treatment with Rivaroxaban of Low-risk Venous Thromboembolism Diagnosed in Two U.S. Emergency Departments: A One-year Preplanned Analysis

Academic Emergency Medicine

Volumn 22, Issue 7, 2015, Pages 789-795

  Beam, Daren M ^a   Kahler, Zachary P ^a   Kline, Jeffrey A ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; RIVAROXABAN; ANTICOAGULANT AGENT;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ASSESSMENT TOOL; CLINICAL EFFECTIVENESS; COMORBIDITY; CONFIDENCE INTERVAL; DEEP VEIN THROMBOSIS; EMERGENCY WARD; FEMALE; FOLLOW UP; HESTIA CRITERIA; HOME CARE; HOSPITAL DISCHARGE; HUMAN; INTERNATIONAL SOCIETY OF THROMBOSIS AND HEMOSTASIS; LOW RISK PATIENT; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MENORRHAGIA; MIDDLE AGED; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; SAFETY; TREATMENT OUTCOME; UNITED STATES; VENOUS THROMBOEMBOLISM; VERY ELDERLY; YOUNG ADULT; ADOLESCENT; CHEMICALLY INDUCED; CLINICAL TRIAL; EMERGENCY HEALTH SERVICE; ORGANIZATION AND MANAGEMENT; PATIENT SELECTION; PULMONARY EMBOLISM; RISK FACTOR; VENOUS THROMBOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; EMERGENCY SERVICE, HOSPITAL; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PATIENT SELECTION; PROSPECTIVE STUDIES; PULMONARY EMBOLISM; RECURRENCE; RISK FACTORS; RIVAROXABAN; UNITED STATES; VENOUS THROMBOSIS; YOUNG ADULT;

EID: 84937023021     PISSN: 10696563     EISSN: 15532712     Source Type: Journal    
DOI: 10.1111/acem.12711     Document Type: Article

References (32)

1. Vinson DR, Zehtabchi S, Yealy DM,. Can selected patients with newly diagnosed pulmonary embolism be safely treated without hospitalization? A systematic review. Ann Emerg Med 2012; 60: 651-62.
2. Piran S, Le Gal G, Wells PS, et al., Outpatient treatment of symptomatic pulmonary embolism: a systematic review and meta-analysis. Thromb Res 2013; 132: 515-9.
3. Zondag W, Kooiman J, Klok FA, Dekkers OM, Huisman MV,. Outpatient versus inpatient treatment in patients with pulmonary embolism: a meta-analysis. Eur Respir J 2013; 42: 134-44.
4. Bauersachs R, Berkowitz SD, Brenner B, et al., Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-510.
5. Buller HR, Prins MH, Lensin AW, et al., Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-97.
6. Wasserlauf G, Grandi SM, Filion KB, Eisenberg MJ,. Meta-analysis of rivaroxaban and bleeding risk. Am J Cardiol 2013; 112: 454-60.
7. Zondag W, Hiddinga BI, Crobach MJ, et al., Hestia criteria can discriminate high- from low-risk patients with pulmonary embolism. Eur Respir J 2013; 41: 588-92.
8. Zondag W, Mos IC, Creemers-Schild D, et al., Outpatient treatment in patients with acute pulmonary embolism: the Hestia Study. J Thromb Haemost 2011; 9: 1500-7.
9. Kline JA, Yealy DM,. Venous thromboembolism: EINSTEIN transforms anticoagulant therapy in acute PE. Nat Rev Cardiol 2012; 9: 378-80.
10. Zondag W, den Exter PL, Crobach MJ, et al., Comparison of two methods for selection of out of hospital treatment in patients with acute pulmonary embolism. Thromb Haemost 2013; 109: 47-52.
11. Prins MH, Lensing AW, Bauersachs R, et al., Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11: 21.
12. Kline JA, Roy PM, Than MP, et al., Derivation and validation of a multivariate model to predict mortality from pulmonary embolism with cancer: The POMPE-C tool. Thromb Res 2012; 129: e194-9.
13. Kahn SR, Shapiro S, Wells PS, et al., Compression stockings to prevent post-thrombotic syndrome: a randomised placebo-controlled trial. Lancet 2014; 383: 880-8.
14. Kline JA, Mitchell AM, Runyon MS, Jones AE, Webb WB,. Electronic medical record review as a surrogate to telephone follow-up to establish outcome for diagnostic research studies in the emergency department. Acad Emerg Med 2005; 12: 1127-33.
15. Kearon C, Akl EA, Comerota AJ, et al., Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 94.
16. Ageno W, Dentali F, Donadini MP, Squizzato A,. Optimal treatment duration of venous thrombosis. J Thromb Haemost 2013; 11 (Suppl 1): 151-60.
17. Poli D, Palareti G,. Assessing recurrence risk following acute venous thromboembolism: use of algorithms. Curr Opin Pulm Med 2013; 19: 407-12.
18. Rodger MA, Kahn SR, Wells PS, et al., Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008; 179: 417-26.
19. Eichinger S, Heinze G, Kyrle PA,. D-dimer levels over time and the risk of recurrent venous thromboembolism: an update of the Vienna prediction model. J Am Heart Assoc 2014; 3: e000467.
20. Tosetto A, Iorio A, Marcucci M, et al., Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012; 10: 1019-25.
21. MacLean S, Mulla S, Akl EA, et al., Patient values and preferences in decision making for antithrombotic therapy: a systematic review: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 23.
22. Douketis J, Tosetto A, Marcucci M, et al., Patient-level meta-analysis: effect of measurement timing, threshold, and patient age on ability of D-dimer testing to assess recurrence risk after unprovoked venous thromboembolism. Ann Intern Med 2010; 153: 523-31.
23. Cohn DM, Vansenne F, de Borgie CA, Middeldorp S,. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev 2012;(12): CD007069.
24. De Stefano V, Rossi E,. Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives. A review of the Guidelines from Scientific Societies and Working Groups. Thromb Haemost 2013; 110: 697-705.
25. Becattini C, Agnelli G, Schenone A, et al., Aspirin for preventing the recurrence of venous thromboembolism. N Engl J Med 2012; 366: 1959-67.
26. Rymes NL, Lester W, Connor C, Chakrabarti S, Fegan CD,. Outpatient management of DVT using low molecular weight heparin and a hospital outreach service. Clin Lab Haematol 2002; 24: 165-70.
27. Boccalon H, Elias A, Chale JJ, Cadene A, Gabriel S,. Clinical outcome and cost of hospital vs home treatment of proximal deep vein thrombosis with a low-molecular-weight heparin: the Vascular Midi-Pyrenees study. Arch Intern Med 2000; 160: 1769-73.
28. Othieno R, Abu Affan M, Okpo E,. Home versus in-patient treatment for deep vein thrombosis. Cochrane Database Syst Rev 2007;(3): CD003076.
29. Jara-Palomares L, Sanchez-Oro-Gomez R, Elias-Hernandez T, et al., Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients. Thromb Res 2014; 134: 617-21.
30. Kahler ZP, Beam DM, Kline JA,. Cost of treating venous thromboembolism with heparin and warfarin versus home treatment with rivaroxaban. Acad Emerg Med. 2015; 22: 796-802.
31. Chen SY, Wu N, Gulseth M, et al., One-year adherence to warfarin treatment for venous thromboembolism in high-risk patients and its association with long-term risk of recurrent events. J Manag Care Pharm 2013; 19: 291-301.
32. Kimmel SE, Chen Z, Price M, et al., The influence of patient adherence on anticoagulation control with warfarin: results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Arch Intern Med 2007; 167: 229-35.